Allopurinol sodium
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Allopurinol sodium
- Molecular weight
- 158.1
- Structure (SMILES)
- O=c1[n-]cnc2[nH]ncc12.[Na+]
- allopurinol sodium
- Allopurinol sodium
- aloprim
- Aloprim
- 1 5 dihydro 4h pyrazolo 3 4 d pyrimidin 4 one monosodium salt
- 1,5-DIHYDRO-4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE, MONOSODIUM SALT
- 4h pyrazolo 3 4 d pyrimidin 4 one 1 5 dihydro monosodium salt
- 4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE, 1,5-DIHYDRO-, MONOSODIUM SALT
- allopurinol sodium
- Allopurinol sodium
- ALLOPURINOL SODIUM [ORANGE BOOK]
- Allopurinol sodium [WHO-DD]
- allopurinol sodium orange book
- allopurinol sodium salt
- Allopurinol sodium salt
- ALLOPURINOL SODIUM SALT [MI]
- allopurinol sodium salt mi
- allopurinol sodium who dd
- nsc 108836
- NSC-108836
- CAS registry numbers
- 17795-21-0
- ChEMBL ID
- CHEMBL1200477
- InChIKey
- PTJRZVJXXNYNLN-UHFFFAOYSA-M
- RxNorm IDs (RxCUI)
- 80566
- FDA ingredient codes (UNII)
- 428673RC2Z
- 23662349
- 70691471
- 135566116
- Applicant
- MYLAN
- Approval date
- 17 May 1996
- Application number
- NDA020298
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- Xanthine dehydrogenase inhibitor
- Action type
- Inhibitor
- Target
- Xanthine dehydrogenase/oxidase
- Protein identifier
- P47989
Open Targets mechanisms
- Mechanism
- Xanthine dehydrogenase inhibitor
- Action type
- Inhibitor
- Target
- Xanthine dehydrogenase/oxidase
Investigated indications
- Condition
- Fetal Hypoxia
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001793
- Subject identifier
- D005311
Open Targets indications
- Condition identifier
- EFO_1001793
- Highest recorded phase
- 3
Open Targets warnings
- Warning
- Black Box Warning
- Country
- United States
- Event
- acute generalised exanthematous pustulosis
- Reports
- 88
- Reporting signal score
- 130.99
- Event
- acute kidney injury
- Reports
- 632
- Reporting signal score
- 658.587
- Event
- cholestasis
- Reports
- 128
- Reporting signal score
- 143.574
- Event
- dermatitis exfoliative
- Reports
- 94
- Reporting signal score
- 177.295
- Event
- dermatitis exfoliative generalised
- Reports
- 86
- Reporting signal score
- 217.389
- Event
- dilatation intrahepatic duct acquired
- Reports
- 32
- Reporting signal score
- 125.836
- Event
- drug interaction
- Reports
- 357
- Reporting signal score
- 140.742
- Event
- drug rash with eosinophilia and systemic symptoms
- Reports
- 176
- Reporting signal score
- 488.299
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 1,637
- Reporting signal score
- 5,485.21
- Event
- eczema
- Reports
- 114
- Reporting signal score
- 135.727
- Event
- eosinophilia
- Reports
- 326
- Reporting signal score
- 696.125
- Event
- erythema
- Reports
- 318
- Reporting signal score
- 178.609
- Event
- erythema multiforme
- Reports
- 88
- Reporting signal score
- 119.394
- Event
- face oedema
- Reports
- 119
- Reporting signal score
- 138.251
- Event
- gout
- Reports
- 135
- Reporting signal score
- 233.688
- Event
- headache
- Reports
- 64
- Reporting signal score
- 134.26
- Event
- hepatocellular injury
- Reports
- 149
- Reporting signal score
- 178.024
- Event
- human herpesvirus 6 infection
- Reports
- 55
- Reporting signal score
- 141.324
- Event
- hyperkalaemia
- Reports
- 187
- Reporting signal score
- 194.891
- Event
- pancytopenia
- Reports
- 231
- Reporting signal score
- 212.906
- Event
- pemphigoid
- Reports
- 76
- Reporting signal score
- 121.24
- Event
- pruritus
- Reports
- 449
- Reporting signal score
- 207.845
- Event
- purpura
- Reports
- 92
- Reporting signal score
- 149.099
- Event
- pyrexia
- Reports
- 586
- Reporting signal score
- 226.208
- Event
- rash
- Reports
- 521
- Reporting signal score
- 125.542
And 10 more, listed on the interactive page.
Trial references
- NCT00189007
- Dose
- 200mg/m2/day to 400mg/m2/day
- Route
- Intravenous
- How often
- Once daily or in divided doses at 6-, 8-, or 12-hour intervals
- Administer as single infusion or in divided infusions
- Administer the dose as appropriate for the volume of infusate
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 74.69
- Calculated partition coefficient (ALogP)
- 0.06
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 11
- Molecular formula
- C5H3N4NaO
- Monoisotopic mass
- 158.02045501
- Natural product
- No
- 0143-9533
- 65219-380
- 67457-187
- 68083-380
Related records
Trials (175)
- A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
- A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
- A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
- A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
- A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
- A Study of Dotinurad Versus Allopurinol in Participants With Gout
- A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
- A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
- A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
- A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
- A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart
- A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
- A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
- A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Allo HSCT Using RIC and PTCy for Hematological Diseases
- Allo HSCT Using RIC for Hematological Diseases
- Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
- Allopurinol Add-on Treatment for Refractory Mania
Targets (1)
- XDH Xanthine dehydrogenase inhibitor